No data available
No data available
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $55.19M | $62.64M | $27.16M | $1.09M |
| Operating Income | $-55.19M | $-62.64M | $-27.16M | $-1.09M |
| Operating Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income | $-52.40M | $-60.36M | $-25.74M | $8.42M |
| Net Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS (Basic) | $-0.60 | $-2.09 | $0.21 | $0.40 |
| EBITDA | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A |